Researcher
Erwin Dreesen
- Disciplines:Biomarker evaluation, Biopharmaceutics, Pharmacodynamics, Pharmacokinetics, Pharmacotherapy, Computational biomodelling and machine learning
Affiliations
- Department of Pharmaceutical and Pharmacological Sciences (Department)
Member
From1 Oct 2021 → 30 Sep 2022 - Clinical Pharmacology and Pharmacotherapy (Division)
Member
From1 Oct 2019 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Sep 2014 → 30 Sep 2019
Projects
1 - 10 of 15
- Handling of social determinants in pharmacokinetics-pharmacodynamics analyses to enhance equity and inclusion in drug dosing in neonates, children, and adolescentsFrom4 Jan 2024 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Model informed Dosage optimization of Crizanlizumab for the management of Sickle Cell Disease in TanzaniaFrom17 Oct 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Joint pharmacometrics modeling of antimicrobial exposure, biomarkers, and clinical outcome assessments to improve the in silico exploration of dose optimization strategies in critically ill patientsFrom28 Aug 2023 → TodayFunding: FWO Strategic Basic Research Grant
- STRAtified Dosing based on Augmented renal clearance for CEFtriaxone in patients with severe community-acquired pneumonia: STRADA-CEF trial.From1 Oct 2022 → TodayFunding: FWO Applied Biomedical Research (TBM)
- Model-informed precision dosing of tacrolimus in solid organ transplant recipientsFrom27 Jul 2022 → TodayFunding: FWO Strategic Basic Research Grant
- Pharmacodynamics models to bridge the gap between exposure and response to antimicrobial treatmentsFrom1 Oct 2021 → 30 Sep 2023Funding: BOF - projects
- Antibacterial dose optimisation based on augmented renal clearance in adult critically ill patients and selected pediatric patientsFrom1 Oct 2021 → 30 Sep 2022Funding: BOF - postdoctoral mandates
- Master protocol methodological pharmacometrics researchFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gastrointestinal physiology and drug disposition in geriatric patientsFrom5 Aug 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Beyond optimising drug exposure: Pharmacodynamic models to bridge the gap between exposure and response to antimicrobial treatmentsFrom15 Jul 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
41 - 50 of 96
- Quantification and Explanation of the Variability of First-Dose Amikacin Concentrations in Critically Ill Patients Admitted to the Emergency Department: A Population Pharmacokinetic Analysis(2021)
Authors: Erwin Dreesen, Pieter Annaert, Joost Wauters, Wouter Meersseman, Stefanie Desmet, Sandra Verelst, Willy Peetermans
Pages: 653 - 663 - Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity.(2021)
Authors: Lore Vanderbeke, Pierre Van Mol, Yannick Van Herck, Frederik De Smet, Stephanie Humblet-Baron, Kim Martinod, Ingrid Arijs, Bram Boeckx, Francesca Bosisio, Michael Casaer, et al.
Pages: 4117 - 4117 - itraconazole for COVID-19: Preclinical studies and a proof-of-concept randomized clinical trial Laurens (vol 66, 103288, 2021)(2021)
Authors: Laurens Liesenborghs, Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Sebastiaan ter Horst, Erwin Dreesen, Tatjana Geukens, Ewout Landeloos, Bert Vandenberk, Lorenz Van der Linden, et al.
- Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis(2021)
Authors: Matthias Gijsen, Erwin Dreesen, Pieter Annaert, Yves Debaveye, Joost Wauters
- Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study(2021)
Authors: Matthias Gijsen, Erwin Dreesen, Ruth Van Daele, Pieter Annaert, Yves Debaveye, Joost Wauters
- Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation(2021)
Authors: Ruth Van Daele, Erwin Dreesen, Matthias Gijsen, Yves Debaveye, Joost Wauters
Pages: 1234 - 1241 - Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial(2021)
Authors: Laurens Liesenborghs, Dirk Jochmans, Ann Belmans, Iwein Gyselinck, Laure-Anne Teuwen, Sebastiaan ter Horst, Erwin Dreesen, Tatjana Geukens, Ewout Landeloos, Vincent Geldhof, et al.
- Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease(2021)
Authors: Peter Bossuyt, Erwin Dreesen, Séverine Vermeire
Pages: 947 - + - Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn's Disease Likely to Achieve Endoscopic and Biochemical Remission(2021)
Authors: Erwin Dreesen, Debby Thomas
Pages: 111 - + - Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease(2021)
Authors: Erwin Dreesen, Séverine Vermeire
Pages: 106 - 118